Varian CEO rings NYSE opening bell on World Cancer Day

Dow Wilson, president and CEO of radiation oncology firm Varian Medical Systems,...Read more on AuntMinnie.comRelated Reading: Varian posts Q1 revenue gains 1st Taiwanese patients treated with Varian HyperArc Varian gets Chinese trade tariff exemption Varian gets China OK for Halcyon system Varian launches Bravos brachytherapy system
Source: Headlines - Category: Radiology Source Type: news

Related Links:

The aim of this review was to examine efficacy of palliative interventional radiotherapy (IRT) in esophageal cancer compared with other treatment in terms of dysphagia-free survival (DyFS) and safety.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Tags: Review Article Source Type: research
CONCLUSIONS: Penile cancer needs demanding surgery to be cured, surrounded by chemotherapy in node positive patients. Lymph nodes involvement is a major prognostic factor. Thus, inguinal node assessment cannot be neglected. PMID: 31610869 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
High dose-rate (HDR) brachytherapy for recurrent prostate cancer post-radiotherapy is an accepted salvage method. This prospective non-controlled clinical study investigates HDR-like stereotactic body radiotherapy (SBRT) as a less invasive alternative and evaluates efficacy and toxicity in patients with biopsy proven local recurrence. This method appears clinically feasible, with favorable PSA response, disease control to 5 years in the majority of patients, and acceptably low GU and GI toxicity.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Radical cystectomy (RC) is still considered standard of treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) and high-risk non-muscle-invasive bladder cancer (NMIBC) refractory to intravesical therapy in most countries [1]. However, RC has significant morbidity and mortality [2].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
To compare a standard radio-oncological and a surgical biochemical failure definition after combined-modality radiation therapy (CRT) in men with intermediate- and high-risk prostate cancer.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Cervical Cancer Intervention:   Sponsor:   Peking University Third Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
In conclusion, the addition of triapine to cisplatin-radiotherapy improved the rate of metabolic complete response in patients with advanced-stage uterine cervix or vaginal cancers without significant toxicity. A phase III trial adequately powered to evaluate progression-free and overall survival is underway (NCT02466971).
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The objective function considers pairs of dose points and each pair is given a distance-based penalty if the dose is either too high or too low at both dose points. Constraints are included to retain dosimetric indices at acceptable levels. Our model is designed to automate the manual adjustment step in the planning process. In the automatic adjustment step large-scale optimization models are solved. We show reductions of the volumes of the largest hot and cold spots, and the computing times are feasible in clinical practice. PMID: 31610533 [PubMed - as supplied by publisher]
Source: Physics in Medicine and Biology - Category: Physics Authors: Tags: Phys Med Biol Source Type: research
We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation w...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
Whole pelvis radiotherapy (WPRT) may improve clinical outcomes over prostate-only radiotherapy (PORT)in high-risk prostate cancer patients by sterilization of micrometastatic nodal disease provided there is optimal control of the primary site.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | China Health | Taiwan Health